Alethia Young
Stock Analyst at Cantor Fitzgerald
(2.93)
# 1,376
Out of 5,179 analysts
135
Total ratings
53.7%
Success rate
31.86%
Average return
Main Sectors:
Stocks Rated by Alethia Young
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $20.28 | - | 5 | Jul 5, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Overweight | n/a | $57.78 | - | 5 | Jun 20, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $800 → $850 | $737.71 | +15.22% | 9 | Oct 16, 2023 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | $18 | $2.04 | +782.35% | 6 | Sep 12, 2023 | |
| CRIS Curis | Reiterates: Overweight | $60 | $0.56 | +10,701.08% | 3 | Sep 7, 2023 | |
| ELDN Eledon Pharmaceuticals | Reiterates: Overweight | $9 | $2.83 | +218.02% | 2 | Aug 22, 2023 | |
| VSTM Verastem | Reiterates: Overweight | $34 | $5.04 | +574.60% | 2 | Jul 6, 2023 | |
| BIIB Biogen | Maintains: Neutral | $427 → $327 | $183.84 | +77.87% | 7 | Oct 15, 2021 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $285 → $281 | $433.07 | -35.11% | 5 | Jun 11, 2021 | |
| AKBA Akebia Therapeutics | Initiates: Overweight | $8 | $1.34 | +497.01% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $98 | $1.17 | +8,276.07% | 3 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $295 | $348.77 | -15.42% | 9 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $84 → $86 | $134.25 | -35.94% | 3 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $48 | $31.75 | +51.18% | 4 | Oct 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $4.31 | +596.06% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $72 | $29.43 | +144.65% | 8 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $5 | $1.26 | +296.83% | 5 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $83 → $100 | $90.30 | +10.74% | 6 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $185 → $201 | $216.95 | -7.35% | 6 | Apr 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $86 → $85 | $66.13 | +28.53% | 5 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $32 | $14.27 | +124.25% | 1 | Mar 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $211 → $217 | $19.97 | +986.63% | 12 | Feb 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $48 | $57.40 | -16.38% | 4 | Oct 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $14.36 | - | 3 | Mar 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $151 → $154 | $317.36 | -51.47% | 5 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $113 → $116 | $54.14 | +114.26% | 2 | Mar 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $147 → $106 | $6.08 | +1,643.42% | 8 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $28 | $12.37 | +126.35% | 1 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $82 | $192.49 | -57.40% | 2 | Sep 27, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | n/a | $522.83 | - | 1 | Mar 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.70 | - | 1 | Oct 18, 2016 |
Arcus Biosciences
Jul 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $20.28
Upside: -
Arrowhead Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $57.78
Upside: -
Regeneron Pharmaceuticals
Oct 16, 2023
Maintains: Neutral
Price Target: $800 → $850
Current: $737.71
Upside: +15.22%
ALX Oncology Holdings
Sep 12, 2023
Reiterates: Overweight
Price Target: $18
Current: $2.04
Upside: +782.35%
Curis
Sep 7, 2023
Reiterates: Overweight
Price Target: $60
Current: $0.56
Upside: +10,701.08%
Eledon Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $9
Current: $2.83
Upside: +218.02%
Verastem
Jul 6, 2023
Reiterates: Overweight
Price Target: $34
Current: $5.04
Upside: +574.60%
Biogen
Oct 15, 2021
Maintains: Neutral
Price Target: $427 → $327
Current: $183.84
Upside: +77.87%
Vertex Pharmaceuticals
Jun 11, 2021
Maintains: Overweight
Price Target: $285 → $281
Current: $433.07
Upside: -35.11%
Akebia Therapeutics
Mar 8, 2021
Initiates: Overweight
Price Target: $8
Current: $1.34
Upside: +497.01%
Feb 25, 2021
Maintains: Overweight
Price Target: $86 → $98
Current: $1.17
Upside: +8,276.07%
Feb 3, 2021
Maintains: Overweight
Price Target: $280 → $295
Current: $348.77
Upside: -15.42%
Oct 29, 2020
Reiterates: Overweight
Price Target: $84 → $86
Current: $134.25
Upside: -35.94%
Oct 28, 2020
Maintains: Overweight
Price Target: $30 → $48
Current: $31.75
Upside: +51.18%
Oct 12, 2020
Initiates: Overweight
Price Target: $30
Current: $4.31
Upside: +596.06%
Jul 31, 2020
Maintains: Overweight
Price Target: $70 → $72
Current: $29.43
Upside: +144.65%
Jun 2, 2020
Assumes: Overweight
Price Target: $5
Current: $1.26
Upside: +296.83%
May 19, 2020
Maintains: Neutral
Price Target: $83 → $100
Current: $90.30
Upside: +10.74%
Apr 20, 2020
Reiterates: Overweight
Price Target: $185 → $201
Current: $216.95
Upside: -7.35%
Apr 8, 2020
Reiterates: Overweight
Price Target: $86 → $85
Current: $66.13
Upside: +28.53%
Mar 6, 2020
Maintains: Overweight
Price Target: $30 → $32
Current: $14.27
Upside: +124.25%
Feb 27, 2020
Reiterates: Overweight
Price Target: $211 → $217
Current: $19.97
Upside: +986.63%
Oct 3, 2019
Maintains: Neutral
Price Target: $75 → $48
Current: $57.40
Upside: -16.38%
Mar 22, 2018
Downgrades: Underperform
Price Target: n/a
Current: $14.36
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $151 → $154
Current: $317.36
Upside: -51.47%
Mar 2, 2018
Maintains: Outperform
Price Target: $113 → $116
Current: $54.14
Upside: +114.26%
Jan 24, 2018
Maintains: Outperform
Price Target: $147 → $106
Current: $6.08
Upside: +1,643.42%
Nov 3, 2017
Maintains: Outperform
Price Target: $24 → $28
Current: $12.37
Upside: +126.35%
Sep 27, 2017
Maintains: Neutral
Price Target: $85 → $82
Current: $192.49
Upside: -57.40%
Mar 16, 2017
Initiates: Underperform
Price Target: n/a
Current: $522.83
Upside: -
Oct 18, 2016
Initiates: Outperform
Price Target: n/a
Current: $2.70
Upside: -